Review
Medicine, General & Internal
Mengyuan Lyu, Hongli Lai, Yili Wang, Yanbing Zhou, Yi Chen, Dongsheng Wu, Jie Chen, Binwu Ying
Summary: Alternative splicing is a conserved mechanism that enhances the diversity of transcriptome and proteome by removing introns and ligating exons. Different organisms, including mammals, pathogens, bacteria, and viruses, employ distinct strategies to perform alternative splicing. Infection-related changes in splicing behaviors and regulators can lead to alterations in global splicing profiles, which are enriched in pathways related to immune response, growth, and metabolism. Targeted agents based on infection-specific alternative splicing events have been developed to combat pathogens.
CHINESE MEDICAL JOURNAL
(2023)
Review
Pharmacology & Pharmacy
Ryuichi Sakate, Tomonori Kimura
Summary: Drug repositioning is an effective approach for developing drugs for rare and intractable diseases. Preparation of ontology is crucial for drug development in these diseases, as disease names are inconsistently used worldwide. Ontology-based analysis of clinical trial data has revealed the active occurrence of drug repositioning in rare and intractable diseases, with drugs and their target genes playing a key role in exploring repositionable drugs.
DRUG DISCOVERY TODAY
(2022)
Article
Chemistry, Medicinal
Yi Hua, Xiaowen Dai, Yuan Xu, Guomeng Xing, Haichun Liu, Tao Lu, Yadong Chen, Yanmin Zhang
Summary: Compared with traditional drug discovery, drug repurposing offers a cost-effective and efficient approach. Some drugs may show better effects in different diseases than their original indications. Drug repurposing has proven to be valuable, especially in addressing public health emergencies such as the COVID-19 pandemic.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Biochemistry & Molecular Biology
Sai M. Akilesh, J. Rajesh, Dhanabal Palanisamy, Ashish Wadhwani
Summary: COVID-19 is a global pandemic caused by the novel coronavirus 2 (SARS-CoV-2), requiring rapid and effective antiviral therapies to control the spread of the disease and alleviate symptoms. Drug repurposing strategy offers an attractive approach due to similarities with other coronaviruses, accelerating screening and development proving critical for patient survival.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
(2021)
Article
Biology
Gerda Cristal Villalba Silva, Thiago Steindorff, Roselena Silvestri Schuh, Natalia Cardoso Flores, Ursula Matte
Summary: This study aimed to identify drugs for treating cardiovascular disease in MPS patients and provided good practices for repositioning analysis. The results suggest that pirfenidone and colchicine are promising drug candidates.
Review
Pharmacology & Pharmacy
Guojun Sun, Dashun Dong, Zuojun Dong, Qian Zhang, Hui Fang, Chaojun Wang, Shaoya Zhang, Shuaijun Wu, Yichen Dong, Yuehua Wan
Summary: Drug repurposing has become an effective approach to drug discovery. This study provides a bibliometric analysis of drug repurposing publications from 2010 to 2020. The findings show that the United States leads in this area of research, followed by China, the United Kingdom, and India. The Chinese Academy of Science published the most research studies, and NIH ranked first on the h-index. COVID-19/SARS-CoV-2/coronavirus is the most popular topic for current drug repurposing research.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Karsten Menzel, Jacqueline B. McCrea, Craig Fancourt, Rose Witter, Tian Zhao, S. Aubrey Stoch, Marian Iwamoto
Summary: Letermovir inhibits OAT3 both in vitro and in vivo, there is a likelihood of drug-drug interaction with acyclovir, a substrate of OAT3. A study was conducted to evaluate the effect of letermovir on acyclovir pharmacokinetics in healthy participants. The results showed no clinically significant interaction between letermovir and acyclovir, indicating no dose adjustment is required for coadministration.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Review
Immunology
Laura Matarazzo, Paulo J. G. Bettencourt
Summary: The success of mRNA-based vaccines against COVID-19 has sparked interest in mRNA technology for vaccinology. Since 2020, there has been a significant increase in the development of mRNA vaccines, with improvements in formulation design, delivery methods, and manufacturing processes. However, challenges such as high raw material costs, lack of standardization, and delivery optimization remain. mRNA technology holds promise for addressing emerging infectious diseases and hard-to-treat diseases such as malaria, tuberculosis, and HIV/AIDS.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Infectious Diseases
Vitoria S. Foletto, Tacieli F. da Rosa, Marissa B. Serafin, Angelita Bottega, Rosmari Horner
Summary: Drug repositioning has become an attractive alternative for treating infections caused by multidrug resistant microorganisms due to the global spread of microbial resistance and challenges in discovering new antibiotics. Various non-antibiotic drugs have shown significant antimicrobial activity, especially when combined with antibacterials, and the presence of aromatic rings in the molecular structure contributes to this activity. This review highlights the potential repositioning of non-antibiotic drugs as promising candidates for treating severe bacterial infections caused by extensively resistant bacteria.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Article
Biochemical Research Methods
A. K. M. Azad, Mojdeh Dinarvand, Alireza Nematollahi, Joshua Swift, Louise Lutze-Mann, Fatemeh Vafaee
Summary: Drug similarity studies aim to explore similar therapeutic actions among drugs, utilizing various sources of evidence to derive a multi-modal drug-drug similarity network. The resulting database, DrugSimDB, provides an exhaustive platform for identifying validated repositioning candidates and in-silico drug development applications.
BRIEFINGS IN BIOINFORMATICS
(2021)
Article
Biochemical Research Methods
Xinxing Yang, Genke Yang, Jian Chu
Summary: Computational drug repositioning technology is an effective tool for accelerating drug development. However, existing models have limitations such as a large number of unvalidated drug-disease associations and issues with the inner product. This study proposes a novel PUON framework to address these deficiencies and extensive experiments on four real-world datasets showed that the PUON model achieved the best performance based on six evaluation metrics.
IEEE-ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS
(2023)
Review
Biochemistry & Molecular Biology
Sha Zhu, Qifeng Bai, Lanqing Li, Tingyang Xu
Summary: Drug repositioning plays a significant role in drug development and machine learning methods can accelerate this process. This article focuses on the repurposing potential of type 2 diabetes mellitus drugs for various diseases.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Article
Immunology
Thomas J. Dilworth, Lucas T. Schulz, Warren E. Rose
Summary: Vancomycin therapy often involves empirical use without the necessity of AUC monitoring. Guidelines recommending AUC monitoring are based on limited evidence and should be used cautiously.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Nanoscience & Nanotechnology
Neelam Yadav, Jagriti Narang, Anil Kumar Chhillar, Jogender Singh Rana
Summary: Infectious and hereditary diseases are the primary cause of human mortality globally. CRISPR technology, as an innovative genome editing technology, has shown high sensitivity in therapeutics and can quickly and accurately investigate different pathogens.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Reyhan Metin, Ebru Demet Akten
Summary: Drug repositioning, as a widely used drug design approach, was employed in this study to screen potential modulators for the ligand-binding domain of human glucocorticoid receptor using structure-based pharmacophore modelling and docking. New compounds were discovered by screening existing drug compounds to provide fast and explicit solutions.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2022)
